Partners Group sells Voyage Care, a leading UK specialist care provider

Partners Group

London, UK; 14 January 2022

  • Voyage Care supports over 3,500 people and has more than 10,000 staff
  • The Company has industry-leading quality ratings from the Care Quality Commission
  • During its ownership, Partners Group invested in increasing the scale and quality of care

Partners Group, a leading global private markets firm, acting on behalf of its clients, and Duke Street, a European mid-market private equity group, have agreed to sell Voyage Care (or “the Company”), a provider of specialist care in the UK, to Wren House, the London-based global infrastructure investment manager.

Founded in 1988 and headquartered in Lichfield, Voyage Care provides specialist care and support to people with learning and physical difficulties, brain injuries, autism, and other complex needs across the UK. A large majority of those supported by the Company typically require high levels of support throughout their lives. Voyage Care supports over 3,500 people and has more than 10,000 members of staff. The Company’s commitment to delivering the highest quality care is demonstrated by its industry-leading quality ratings. In England, 95%[1] of Voyage Care’s registered care homes are rated as ‘Good’ or ‘Outstanding’ by the independent Care Quality Commission, which far exceeds the market standard.

Partners Group and Duke Street acquired Voyage Care in 2014 alongside its management team. Key value creation initiatives introduced during the past seven years of ownership include deepening the healthcare experience of its best-in-class management team with key strategic hires, continuing to invest in increasing its market-leading quality of care, further developing its specialisms, and expanding capacity via developments and select acquisitions. Voyage Care is well-positioned to continue consolidating the specialist care market whilst achieving its purpose of providing great quality care and support to those it serves.

Andrew Cannon, Chief Executive Officer, Voyage Care, comments: “Voyage Care has a strong operational and reputational track record which has been driven by the successful execution of our growth strategy. Partners Group and Duke Street have been hugely supportive, investing in the key resources needed to maintain our position as a leading specialist care provider in the UK. We strive to deliver the highest possible levels of care across all our communities, as well as attract and retain the most skillful and dedicated care professionals.”

Andrew Deakin, Managing Director, Private Equity Services, Partners Group, says: “Voyage Care makes a lifelong difference to the people and families it supports, which resonates strongly with Partners Group’s mission to create lasting, positive stakeholder impact. During our holding period, we worked with Voyage Care’s experienced management team to grow the Company sustainably, whilst ensuring it never lost sight of its mission to deliver the highest-quality care. We firmly believe that Voyage Care now has solid foundations on which to build and continue its success story.”

Remy Hauser, Managing Director, Private Equity Health & Life, Partners Group, adds: “The specialist care market remains highly fragmented in the UK, with a range of different providers catering to very specific needs. This has created growth opportunities for Voyage Care, which has acquired and carefully integrated several specialist learning and pediatrics care providers during our ownership, in addition to organically expanding its business to meet changing needs. Through this dual approach, Voyage Care has helped to ensure consistently high standards of care quality across its different specialisms. We wish the management team all the best for the future.”

Categories: News

Tags:

Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe

Andera Partners

Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royalties
• ADVANZ gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom, Switzerland, and Norway
• Cefepime/enmetazobactam has completed a Phase III clinical trial against standard of care in treating complicated urinary tract infection, including acute pyelonephritis

ADVANZ PHARMA Corp. Limited (“ADVANZ PHARMA”), a specialty pharmaceutical company with a strategic focus on hospital medicines in Europe, and Allecra Therapeutics (“Allecra”) today announced that the companies have signed an exclusive license agreement under which ADVANZ PHARMA gains the rights to develop and commercialize Allecra’s antibiotic drug candidate cefepime/enmetazobactam within the European Union, the United Kingdom, Switzerland, and Norway. In exchange for the exclusive license, Allecra will receive an upfront payment and development and sales milestones for cefepime/enmetazobactam, as well as double-digit tiered royalties. In addition, the two companies have signed a supply agreement under which Allecra will supply the cefepime/enmetazobactam finished product in the agreed upon territories. No further financial details have been disclosed.

“ADVANZ PHARMA is building a leadership position in Europe as a specialty pharmaceutical company and they are an ideal commercialization partner for Allecra as we advance toward regulatory submission for cefepime/enmetazobactam,” stated Andreas Kranzusch, Chief Financial Officer at Allecra Therapeutics. “This agreement, together with our license agreement with Shanghai Haini for commercialization in China, reflects the understanding that there remains a need worldwide to address the dangerous increase of resistance  to standard-of-care antibiotics. The pandemic has only heightened this awareness.”

Graeme Duncan, Chief Executive Officer of ADVANZ PHARMA, commented: “The importance of antibiotics and the quest to find new agents to overcome the issue of increasing resistance cannot be underestimated. As we continue to push forward with our goal to become the partner of choice for commercializing hospital medicines in Europe, this is a great addition to our anti-infectives portfolio, and will further help enhance choice and access for patients. We look forward to adding cefepime/enmetazobactam to our portfolio upon regulatory approval.”

Cefepime/enmetazobactam is a combination of enmetazobactam, a extended-spectrum β- lactamase inhibitor, combined with the 4th generation cephalosporin cefepime. Due to their efficacy and safety, β-Lactams are the most widely used class of antibiotics, referred to commonly as penicillins and related β-lactam classes of cephalosporins, and cephamycins, among other names. Due to the extensive use, a growing number of pathogens have become resistant to a wide range of β-lactam antibiotics, posing a growing risk in both developed and developing countries. In the US alone, Extended-Spectrum β-lactam Resistant Pathogens (ESBLs) have increased >50% over a 6-year period. The consummation of the licensing transaction is subject to regulatory approval and other customary conditions precedent.

Categories: News

Tags:

Arseus Medical Group announces new partnership with Heart Medical Europe BV

GIMV

13/01/2022 – 09:00 | Portfolio

Heart Medical Europe BV is a distributor of interventional (paediatric) cardiology, interventional radiology and cardio-thoracic surgery products in the Benelux. As a Belgian top player and reference in the distribution of medical and paramedical products, Arseus Medical wants to be a partner in innovation for the healthcare sector and offer their customers the best brands in their domain.

We are convinced that this partnership makes both the Arseus Medical Group and Heart Medical Europe BV a lot stronger. The motto of our group is ‘Together strong in patient care’. As a distributor, we want to be a partner to our customers in the healthcare sector in terms of

innovation and expertise. We want to be a house of specialists that our customers can rely on. And Heart Medical’s philosophy fits in nicely with that. The extensive expertise of their people over the years has enabled them to build a strong position and make a difference for their customers.
We look forward to setting out on the road to further growth and innovation together in 2022.

Categories: News

Tags:

RLDatix Announces New Growth Investment by Nordic Capital

Nordic Capital
January 10 2022
RLDatix Announces New Growth Investment by Nordic Capital Image

 

  • Latest investment will help fuel the next phase of RLDatix’s rapid growth in governance, risk and compliance while accelerating its mission of making healthcare safer around the world

RLDatix, the international leader in governance, risk and compliance (GRC) solutions for healthcare, announced today that Nordic Capital has made a minority equity investment in the company. Existing investors Five Arrows and TA Associates will continue to maintain a majority equity stake. Financial terms of the transaction were not disclosed.

Nordic Capital brings decades of experience supporting the growth of innovative healthcare IT companies as well as additional financial strength and is joining Five Arrows and TA to support RLDatix in its organic and inorganic growth objectives. Most recently, RLDatix acquired Allocate Software, the leading provider of human capital management solutions that help healthcare organizations deliver safe and effective care.

“We are excited to welcome Nordic Capital to our collaborative team of strategic investors,” said Jeff Surges, CEO, RLDatix. “Nordic Capital offers the right balance of global reach, domain expertise and capital strength, that we need in our next phase of rapid growth. With this investment, we are well poised to accelerate our journey as the leading provider of SaaS solutions that make healthcare safer for patients, the workforce and organizations alike. I would also like to thank all of our employees, as well as our current investors Five Arrows and TA, for their incredible support in helping us evolve into a global healthcare IT leader and look forward to continuing the partnership in this next chapter of our growth.”

About RLDatix

RLDatix is on a mission to change healthcare. We help organizations drive safer, more efficient care by providing governance, risk and compliance tools that drive overall improvement and safety. Our suite of cloud-based software helps organizations report on adverse events, reduce healthcare-acquired infections and ensure patient safety learnings are implemented across the continuum of care. With more than 5,000 customers in over 20 countries, RLDatix software protects hundreds of millions of patients around the world. RLDatix is controlled by Five Arrows, TA Associates and Nordic Capital as major shareholders. For more information, visit www.rldatix.com.

About Nordic Capital

Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and selectively, Industrial & Business Services. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested more than EUR 19 billion in over 120 investments. The most recent entities are Nordic Capital X with EUR 6.1 billion in committed capital and Nordic Capital Evolution with EUR 1.2 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway and South Korea. For further information about Nordic Capital, please visit www.nordiccapital.com.

“Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”

About Five Arrows

Five Arrows Principal Investments (FAPI) and Five Arrows Capital Partners (FACP) (together, “Five Arrows”) are the European and US corporate private equity arms, respectively, of Rothschild & Co’s Merchant Banking business. Five Arrows is focused on investing in middle-market companies with highly defensible market positions; strong management teams; business models with high visibility of organic unit volume growth and strong free cash flow conversion; and multiple operational levers that can be used to unlock latent value. The sector focus at Five Arrows is limited to healthcare, data & software and technology-enabled business services.

For more information please visit: https://www.rothschildandco.com/en/merchant-banking/corporate-private-equity.

About TA Associates
TA is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – the firm invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 550 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $47.5 billion in capital since its founding in 1968. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com.

For more information:

Mike Etzinger
VP, Marketing
RLDatix
metzinger@rldatix.com

Categories: News

Tags:

KKR Closes $4.0 Billion Health Care Strategic Growth Fund II

KKR

January 10, 2022

Successor Fund Reaffirms Firm’s Commitment to Investing in Innovative Health Care Growth Companies

MENLO PARK, Calif. & NEW YORK–(BUSINESS WIRE)– KKR, a leading global investment firm, today announced the final closing of KKR Health Care Strategic Growth Fund II (“HCSG II” or the “Fund”), a $4.0 billion fund dedicated to health care growth equity investment opportunities primarily in North America and Europe.

HCSG II is the successor fund to KKR Health Care Strategic Growth Fund (“HCSG I”), KKR’s first dedicated health care growth equity vehicle, which held its final closing in November 2017 on $1.45 billion in capital commitments. Similar to its predecessor fund, HCSG II will aim to generate strong returns for clients by investing in innovative health care companies with proven products and services that are seeking a partner to commercialize and scale. With a diversified portfolio approach, HCSG II will focus on the biopharmaceutical, medical device, health care services, life science tools / diagnostics, and health care information technology sub-sectors.

“Now more than ever there is a significant demand both for innovative products and services in the health care sector and for an experienced and flexible capital partner to invest in their growth and further their reach,” said Ali Satvat, Partner, Global Head of Health Care Strategic Growth, and Co-Head of Americas Health Care Private Equity at KKR. “Building on the robust momentum and tangible results that we have achieved thus far through HCSG I, we look forward to continuing to partner with best-in-class health care businesses to bring these much-needed products and services to market for the benefit of patients globally while delivering strong returns for our investors.”

HCSG II received strong support from a diverse group of both new and existing investors globally, including public pension plans, sovereign wealth funds, insurance companies, financial institutions, endowments, private wealth and fintech platforms, family offices, and high-net-worth individual investors. KKR will be investing approximately $500 million of capital in the Fund alongside these investors through the Firm’s balance sheet, affiliates, and employee commitments.

“We are pleased to have the backing of this diverse group of investors who share our passion for the opportunities that we see in this growing market,” said Alisa Amarosa Wood, Partner and Head of the Private Markets Strategies Group at KKR. “At nearly three times the size of its predecessor, HCSG II not only speaks to the attractive investment opportunities that we are seeing but also demonstrates the strength of our health care investment team, our Health Care Strategic Growth strategy, and our strong investment performance to date.”

KKR has established a strong track record of supporting companies across the health care ecosystem, having invested approximately $18 billion across the sector since 2004. KKR’s health care team has grown to nearly 35 dedicated investment professionals globally. In addition to providing capital, the Firm helps companies grow through its industry experience and relationships, operational expertise, global infrastructure, and resources from more than 100 portfolio companies worldwide. In 2021, KKR executed a number of new investments as part of its Health Care Strategic Growth initiatives, including in Argenta, Nordic Bioscience, Sapphiros, Geode Health, and Cordis.

About KKR

KKR is a leading global investment firm that offers alternative asset management and capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit, and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life, and reinsurance products under the management of The Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

Media:
Cara Major or Julia Kosygina
212-750-8300
media@kkr.com

Source: KKR & Co. Inc.

Categories: News

Tags:

Welby Health Partners with New Stack Ventures to Usher in a New Era of Tech-Enabled Care

New Stack Ventures

Revolutionizing Modern Healthcare through a Unique RPM Solution

January 9, 2022 · New Investment

When it comes to healthcare, the United States has become a leader in strategic innovations to improve patient care, outcomes, and the patient experience. That said, when it comes to chronic conditions that plague millions of Americans annually, there are few resources available to maintain top-tier healthcare from home. However, Welby Health, whose revolutionary WelbyCare platform to enhance at-home, longitudinal care, has recently closed a seed funding round from New Stack Ventures. The capital infusion will help Welby progress toward its goal to offer physicians and patients across the nation access to best-in-class support for the management of chronic diseases.

Created by doctors, for doctors, the WelbyCare platform was designed to help physicians manage patients with chronic conditions and complex health needs from their homes. CEO Seth Merritt works with an outstanding clinical team led by Dr. Taib Rawi, to ensure that the WelbyCare program is an extension of clinical practices, and provides physicians and patients greater support in managing chronic health conditions like diabetes and hypertension. Welby is combining a licensed clinical staff with hardware and software–including biometric data collection and digital engagement tools–to support physician offices in promoting patient engagement outside of the clinic.

“Physicians are already overworked, and asking them to take the burden of managing patients outside of the clinic themselves is just not realistic. By providing an opportunity to promote our tech-enabled clinical services to more physicians, we will be able to impact the lives of more patients and help them improve their health outcomes while also helping physicians get more enjoyment out of their profession” says Merritt.

In addition to a state-of-the-art remote patient monitoring program, the WelbyCare platform provides clinics with nationally recognized and clinically validated care guidelines to generate patient-specific care plans that comply with NCQA requirements for value-based care. Access to this level of clinical support would typically cost a clinic more than $20K annually to license and deploy, but the WelbyCare platform provides access to these guidelines to all participating clinics for no additional cost or fees, enabling the greatest possible outcomes from their remote patient monitoring programs.

By partnering with New Stack Ventures, Welby Health will be able to leverage its proprietary technology platform to break into new markets, reach new physicians, and partner with renowned clinics across the country to bring the future of healthcare to the millions of Americans requiring oversight to their chronic conditions while reducing the total cost of care. WelbyCare leverages the expertise of registered nurses and certified case managers for all patient-facing interactions, as opposed to other programs that often use non-clinically trained administrative staff that may satisfy regulatory requirements but have failed to deliver significant clinical results that physicians are looking for.

Austin Ju, deal lead at New Stack Ventures noted, “Remote patient monitoring is one of the fastest-growing segments in healthcare, projected to reach $117B by 2025. Despite this, existing solutions face poor adoption and retention. Welby’s white-gloved approach with their clinical partners addresses these major concerns.”

To learn more about Welby Health, please visit: https://www.welby.care/

Categories: News

Tags:

ProcessMAP partners with Hg

HG Capital

ProcessMap partners with Hg, a global software investor, to accelerate its strategy towards becoming a global software leader in worker health and safety management

Hg’s strategic investment will accelerate ProcessMAP’s position towards a category leader in the rapidly growing EHS Risk and Compliance software sector.

Ft. Lauderdale, Florida, USA and New York, New York, USA.  5 January 2022.

ProcessMAP Corporation (“ProcessMAP”), a leading Environmental, Health and Safety (“EHS”) software platform provider, announced today that Hg, a leading software and services investor with nearly $40 billion funds under management, has agreed to make a significant investment in the business to accelerate ProcessMAP’s growth and expansion, and help solidify the company’s position as a global leader in the EHS software sector.

Following the transaction, ProcessMAP’s management team will retain a significant stake in the business. The terms of the transaction are not disclosed.

Founded in 2000, ProcessMAP’s vision is to enable businesses to proactively mitigate workplace health and safety risks for workers. ProcessMAP’s SaaS and mobile solutions serve mid-market and enterprise customers across large industry verticals such as automotive and manufacturing. ProcessMAP’s solutions are used by global customers in more than 140 countries, covering 2 million workers across 80,000 sites. Headquartered in Florida, ProcessMAP has nearly 300 employees based in the USA, Canada, the UK, Germany and India. The company is regularly recognized as a “Leader” in the biennial Green Quadrant report for EHS software published by Verdantix, an independent industry analyst for the EHS sector.

Accelerating the Innovation Momentum for ProcessMAP Customers

ProcessMAP will leverage the financial investment as well as Hg’s 20+ years of industry-leading experience in building and rapidly growing innovative software businesses.  The financial partnership with Hg will also enable ProcessMAP to deliver next-generation, smart and connected EHS solutions to its customers globally. Additionally, the company will also make investments to expand its team globally, strengthen its position further, and broaden its global customer base, particularly in Europe and Asia-Pacific.

Comments on the News

“We share our customers’ commitment to create and offer the safest and the healthiest workplaces, while minimizing the environmental impact of day-to-day operations. Bringing in Hg to invest in our business comes at a very interesting time as we see an opportunity to help customers protect millions more workers globally.”

Dave Rath, CEO and Co-Founder of ProcessMAP

“This partnership, built on software knowledge and experience, will enable us to develop our analytics-driven software further, helping more customers across the globe optimize their EHS processes while, critically, mitigating operational and sustainability risk.”

Jagan Garimella, CTO and Co-Founder of ProcessMAP

“Hg has been focused on risk and compliance software for two decades and we see strong tailwinds continuing to drive demand in this sector. The impressive work from Dave Rath, Jagan Garimella, and the team means that ProcessMAP is well-positioned to benefit from this dynamic. They’ve built a high-quality platform which receives consistent, strong feedback from a loyal customer base. We believe that together, Hg and ProcessMAP, will form a strong partnership and we look forward to supporting the team, investing in the business and continuing to realize its growth potential.”

Ben Meyer, Partner at Hg

KPMG Corporate Finance acted as the exclusive investment banking advisor to ProcessMAP.


Media Contacts

Hg
Tom Eckersley
Tom.Eckersley@hgcapital.com
+44 208 148 5401

Alex Yankus and Harry Mayfield (Brunswick, USA)
+1 917 818 5204

ProcessMAP
Sandeep Rath
Director, Global Product Marketing and Analyst Relations
srath@processmap.com

About ProcessMAP Corporation

ProcessMAP Corporation is the most trusted name for a digitization and process transformation platform that empowers customers to ensure workers’ health & safety, minimize risk, and assure compliance. The ProcessMAP Platform includes solutions for Environmental, Health and Safety (EHS), Environmental, Social and Governance (ESG), and Operational Risk Management (ORM), Industrial IoT, and actionable data analytics to connect people, systems, assets, and facilities to drive a Sustainable Enterprise. ProcessMAP is headquartered in Ft. Lauderdale, Florida, with locations across the globe, serving customers in over 140 countries. Visit https://www.processmap.com/ to learn more.

About Hg

Hg is a growth platform for software and services champions, focused on backing businesses that change how we all do business. Deep technology expertise, complemented by vertical application specialisation and dedicated operational support, provides a compelling proposition to management teams looking to scale their businesses. Hg has funds under management of around $40 billion, with an investment team of over 140 professionals, plus a portfolio team of around 40 operators, providing practical support to help our businesses to realise their growth ambitions. Based in London, Munich and New York, Hg has a portfolio of over 35 software and technology businesses, worth around $92 billion aggregate enterprise value, with over 55,000 employees globally, growing at over 20% per year. Visit www.hgcapital.com for more information.

Categories: News

Tags:

RTI Surgical announces spin-off of businesses into two independent companies

Montagu

Metals business will become Resolve Surgical Technologies
Tissues & Biologics business will retain the RTI Surgical name

 

RTI Surgical, a global private label OEM company, announced today that the company will spin off its Metals business, creating two independent companies that are focused on the needs of customers and patients in their distinct market segments. Ownership of both companies will be retained by Montagu, a leading private equity firm specialized in finding and growing businesses that make the world work.

As industry-leading surgical implant suppliers, both businesses partner with leading medical technology companies to design and develop medical devices. The spin-off will reinforce market focus for both the Metals and Tissue & Biologics businesses and better position each company to capitalize on strategic growth opportunities as the need for outsourced private label medical device manufacturing and product life cycle management increases.

 

Metals Business Introduces New Market Brand

As a result of the spin-off, the Metals business, which acts as a full-service partner covering design, development, manufacturing, and regulatory support of metal and polymer implants and instruments used in orthopedics, spine and cardiothoracic applications, will change its name and market brand to Resolve Surgical Technologies. The new name reflects the company’s commitment to resolve customers’ end-to-end manufacturing and product lifecycle challenges, so they are free to focus on their strategic priorities.

The current President of the Metals business, Megan Osorio, will become CEO of Resolve Surgical Technologies, focusing on meeting the growing demand for fully outsourced solutions, “Since the company was founded 30 years ago, our hallmark has been innovative product development, world-class manufacturing, rigorous quality management, and regulatory expertise. Our new brand carries this equity forward and communicates our exciting direction as an independent company,” said Osorio.

Since the company was founded 30 years ago, our hallmark has been innovative product development, world-class manufacturing, rigorous quality management, and regulatory expertise.

Megan Osorio, CEO, Resolve Surgical Technologies

Resolve Surgical Technologies was founded in Marquette, Mich. in 1992 as Pioneer Surgical Technologies and was acquired by RTI Surgical in 2013. The company will build on its Marquette facility and workforce.

 

Tissues & Biologics Business to Retain RTI Surgical Name

The Tissues & Biologics business, which provides a comprehensive portfolio of tissue-based surgical implants across multiple market segments and commercial channels, will retain the RTI Surgical name. Olivier Visa, CEO, will continue to lead this company, which is based in Alachua, Fla., and has manufacturing facilities in Greenville, N.C. and Neunkirchen, Germany. “Our team is passionate about partnering with our customers to develop and deliver solutions that restore quality of life for patients while maximizing the gift of tissue donation. With RTI Surgical’s singular focus on allograft and xenograft tissue-based implants, our team will provide expanded private label solutions for customers. Our expertise includes design, development, and processing in addition to all aspects of product life cycle management, regulatory compliance and Design History File ownership,” said Visa.

Our team is passionate about partnering with our customers to develop and deliver solutions that restore quality of life for patients while maximizing the gift of tissue donation.

Olivier Visa, CEO, RTI Surgical

RTI was the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of tissue donation. The company was also the first to introduce proprietary, validated, tissue-specific sterilization processes that address the risk of donor-to-recipient disease transmission.

“This is an exciting opportunity for both businesses to pursue their growth potential as strong, independent companies,” said Adrien Sassi, Director at Montagu. “This milestone builds on our expertise in carve-outs and commitment to helping our businesses reach their full potential. We are fully committed to supporting Olivier, Megan and their teams as they build on their respective track records of innovation.”

This is an exciting opportunity for both businesses to pursue their growth potential as strong, independent companies.

Adrien Sassi, Director, Montagu

Categories: News

Tags:

EQT Private Equity and Santo to invest further in WS Audiology

eqt

EQT VIII and Santo Holdings to acquire EQT VI and its co-investors’ stakes in WS Audiology, the number one global pure play producer of hearing aids

WS Audiology is supported by strong, underlying macro trends, such as a growing aging population, urban noise pollution, and increased penetration and growing demand for hearing aids in developing countries

The investment by EQT Private Equity illustrates the long-term commitment and support for WS Audiology’s mission of helping people regain or improve their hear

EQT is pleased to announce that the EQT VIII fund (“EQT VIII” or “EQT Private Equity”) and Santo Holdings (“Santo”), together with co-investors,have agreed to acquire the EQT VI fundand its co-investors’ stakes in WS Audiology (“the Company”). Following the closing of the transaction, EQT VII, EQT VIII, Santo Holdings, the Tøpholm and Westermann families, and a group of minority co-investors, will own WS Audiology.

Headquartered in Lynge, Denmark, WS Audiology is the number one global pure play producer of hearing aids and accessories in terms of volumes with more than 170 years of combined experience and a proven track record as an industry innovator.

WS Audiology was created in February 2019 through the merger of Sivantos, acquired by EQT VI in 2014 and previously named Siemens Audiology Solutions, and Widex, at the time owned by the Tøpholm and Westermann families. As part of the merger EQT VII and EQT VIII jointly invested in the combined company alongside EQT VI, Santo, the Tøpholm and Westermann families, and other minority shareholders. Today, WS Audiology has revenues of more than EUR 2.0 billion, over 11,000 employees and one of the strongest R&D teams in the industry.

WS Audiology operates in a highly attractive market characterized by healthy, non-cyclical growth and broadened addressable customer groups. The Company is supported by underlying trends, such as an overall aging population, urban noise pollution resulting in higher numbers of hearing-impaired people, an increasing penetration of hearing aids users among the hearing impaired thanks to improved technology and social acceptance, and a growing demand for hearing aids in developing countries.

Since acquisition, WS Audiology’s EBITDA has increased more than 20 percent. EQT and the owner families have supported the Company’s efforts to invest significantly in R&D to entrench as the industry innovator, benefitting from a unique digital ecosystem. WS Audiology is the leader in remote fitting of hearing aid equipment through its subsidiary hear.com, and COVID-19 has accelerated tele-audiology and remote fitting trends.

Kasper Knokgaard, Partner within EQT Private Equity Advisory Team, “Every year, WS Audiology helps millions of people around the world to regain or improve their hearing. The Company’s hearing aids not only improve quality of life but they also offer the possibility to change people’s economic opportunities to the better in less developed countries. EQT Private Equity is therefore proud to renew its long-term support for WS Audiology alongside its other co-investors.

The transaction is subject to customary conditions and approvals and it closed in December 2021.

With this transaction, EQT VIII is expected to be 80-85 percent invested (including closed and/or signed investments, announced public offers, if applicable, and less any expected syndication).

Contact
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

About

About EQT
EQT is a purpose-driven global investment organization with more than EUR 70 billion in assets under management across 27 active funds. EQT funds have portfolio companies in Europe, Asia-Pacific and the Americas with total sales of approximately EUR 29 billion and more than 175,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on LinkedInTwitterYouTube and Instagram

About WS Audiology
Formed in 2019, through the merger of Sivantos and Widex, WS Audiology combines over 140 years’ experience in pioneering the use of technology to help people with hearing loss hear the sounds that make life wonderful. With truly differentiated brands like Widex, Signia, Rexton, Audio Service and Vibe, and with diverse assets across wholesale, retail, online, managed care and diagnostic solutions, we are active in over 125 markets. As a global leader, our ambition is to unlock human potential by making wonderful sound part of everyone’s life.

More info: www.wsa.com

Categories: News

Tags:

Gilde Healthcare portfolio Volta Medical treats first U.S. patients with persistent cardiac arrythmias

GIlde Healthcare
December 21, 2021
Marseille, France, Providence (Rhode Island), USA & Utrecht, the Netherlands

Volta Medical, a pioneering health tech company developing artificial intelligence (AI)-based software solutions to treat cardiac arrythmias, today announced the introduction of its leading-edge product, VX1, at three leading U.S. hospitals. New York Presbyterian Queens, Northwell Health’s Lenox Hill Hospital in New York City, and Ascension St. Vincent’s Riverside, Jacksonville, FL, are the first U.S. hospitals to implement VX1, which is designed to improve outcomes for patients undergoing atrial fibrillation (AF) ablation procedures.

 

All three hospitals also are recruiting AF ablation patients to participate in an international, randomized controlled clinical trial to evaluate the outcomes of VX1-guided ablation versus standard ablation called TAILORED-AF trial. The international, multi-center trial will involve 25 sites and 342 patients and is expected to report results in 2024. VX1 is cleared as a medical device by the U.S. Food and Drug Administration and CE-certified by the European Union.

VX1 is the first commercially available AI software to help clinicians combat high failure rates in the use of ablation for treating persistent, drug-resistant AF. AF, characterized by an irregular and chaotic heartbeat (cardiac arrythmia), can lead to more serious health issues such as heart failure and stroke. During AF ablation, a specialized cardiologist known as an electrophysiologist inserts catheters through the blood vessels into the heart to burn or freeze tissue that is causing abnormal electrical signals in the upper chamber, or atrium. The procedure creates scarring that restores a normal heartbeat.

The VX1 system analyzes electrical signals measured during the procedure and identifies abnormalities in real-time. VX1 is versatile and can be installed in most operating rooms and is compatible with the main multipolar catheters and mapping systems.

About atrial fibrillation (AFib or AF)
An estimated 6.1 million people in the United States have AF with projections to reach nearly 12.1 million in 2030. Worldwide, it affects more than 33 million people. Symptoms include palpitations, lightheadedness and shortness of breath. In some patients, AF can lead to heart failure. AF is not only an extremely costly public health issue but also a major risk factor for stroke, posing a 4-to-5 times greater risk than for the general population. AF is commonly treated with medication that regulates or slows the heart rate. For patients who cannot tolerate or are resistant to anti-arrhythmic drug therapy, ablation is the current standard of care. Ablation uses heat or cold energy to create tiny scars in the heart to block abnormal electrical signals and restore a normal heartbeat. However, the efficacy of this approach depends largely on the experience and intuition of the electrophysiologist. With 50% of persistent AF patients requiring repeat treatments, the need for more precise therapies is significant.

About the TAILORED-AF trial
TAILORED-AF is an international, multicenter trial designed to determine if a tailored VX1 AI software-guided ablation strategy targeting areas of spatiotemporal dispersion in combination with pulmonary vein isolation (PVI) is superior to a conventional anatomical ablation strategy targeting PVI alone for the treatment of persistent AF. The primary endpoint of the study is the absence of documented AF episodes > 30 seconds, with or without anti-arrhythmic drugs (AADs), 12 months after a single index ablation procedure. Secondary endpoints include absence of AF and/or atrial tachycardia (AT) episodes after a 12-month period, following one or more procedures, as well as safety. Volta Medical expects results from the TAILORED-AF trial in 2024.

About Volta Medical
Volta Medical is a health tech company developing AI software solutions to assist cardiac electrophysiologists in the operating room. Volta’s overarching goal is to significantly improve cardiac arrythmia management by developing state-of-the-art, data-driven medical devices based on large databases of procedural data with the highest standards of data protection. Founded by three physicians and a data scientist in 2016 in Marseille, France, Volta’s first product, VX1, assists cardiologists in the real-time identification of specific abnormal electrograms, known as dispersed electrograms. For more information, visit the company’s website at www.volta-medical.com.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor with two fund strategies: Venture&Growth and Private Equity. The firm operates out of offices in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Venture&Growth invests in fast growing, innovative companies active in (bio)pharmaceuticals, healthtech and medtech that are based in Europe and North America. For more information, please visit: www.gildehealthcare.com.

Categories: News

Tags: